Featured Studies Results
Cancer: Breast
Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)
https://www.facingourrisk.org/research-clinical-trials/study/359/study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT06841354 (https://clinicaltrials.gov/show/NCT06841354)
Treatment
Treatment study for people with metastatic, triple-negative breast cancer
Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib
Clinicaltrials.gov identifier:
NCT06545942 (https://clinicaltrials.gov/show/NCT06545942)
Treatment
Treatment study for people with advanced or metastatic cancers
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
https://www.facingourrisk.org/research-clinical-trials/study/349/studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01
Clinicaltrials.gov identifier:
NCT06380751 (https://clinicaltrials.gov/show/NCT06380751)
Treatment
Treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
An Online Program to Help Asian American Breast Cancer Survivors Manage Pain and Depression
https://www.facingourrisk.org/research-clinical-trials/study/352/an-online-program-to-help-asian-american-breast-cancer-survivors-manage-pain-and-depression
Clinicaltrials.gov identifier:
NCT06085313 (https://clinicaltrials.gov/show/NCT06085313)
Quality of Life
An online program to help Asian American breast cancer survivors manage pain and depression
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350/treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Clinicaltrials.gov identifier:
NCT06167317 (https://clinicaltrials.gov/show/NCT06167317)
Treatment
Treatment study for people with advanced or metastatic solid tumors
HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/342/heal-abc-study-harnessing-e-mindfulness-approaches-for-living-after-breast-cancer
Clinicaltrials.gov identifier:
NCT06748222 (https://clinicaltrials.gov/show/NCT06748222)
Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression
Sexual Health and Rehabilitation Online (SHAREonline): An Educational Intervention for Young Women after Cancer
https://www.facingourrisk.org/research-clinical-trials/study/323/sexual-health-and-rehabilitation-online-shareonline-an-educational-intervention-for-young-women-after-cancer
Clinicaltrials.gov identifier:
NCT06458049 (https://clinicaltrials.gov/show/NCT06458049)
Quality of Life
An online study comparing two educational interventions for female cancer survivors experiencing sexual health changes
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/345/treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib
Clinicaltrials.gov identifier:
NCT06488378 (https://clinicaltrials.gov/show/NCT06488378)
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/344/study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer
Clinicaltrials.gov identifier:
NCT06401421 (https://clinicaltrials.gov/show/NCT06401421)
Treatment
Biomarker study for people with early-stage breast cancer
Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/343/a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT05929768 (https://clinicaltrials.gov/show/NCT05929768)
Treatment
Treatment study for early-stage triple-negative breast cancer
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Clinicaltrials.gov identifier:
NCT06022029 (https://clinicaltrials.gov/show/NCT06022029)
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
ShareForCures®: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry
https://www.facingourrisk.org/research-clinical-trials/study/295/shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry
Clinicaltrials.gov identifier:
NCT05654246 (https://clinicaltrials.gov/show/NCT05654246)
Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
The WISDOM Study: Women Informed to Screen Depending on Measures of Risk
https://www.facingourrisk.org/research-clinical-trials/study/45/wisdom-study
Clinicaltrials.gov identifier:
NCT02620852 (https://clinicaltrials.gov/show/NCT02620852)
Prevention
Genetic testing and breast cancer screening
Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )
https://www.facingourrisk.org/research-clinical-trials/study/267/observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation
Clinicaltrials.gov identifier:
NCT01443468 (https://clinicaltrials.gov/show/NCT01443468)
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)
https://www.facingourrisk.org/research-clinical-trials/study/271/a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca
Clinicaltrials.gov identifier:
NCT03729115 (https://clinicaltrials.gov/show/NCT03729115)
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.